BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 21907096)

  • 1. Experimental models of HD and reflection on therapeutic strategies.
    Kim J; Bordiuk OL; Ferrante RJ
    Int Rev Neurobiol; 2011; 98():419-81. PubMed ID: 21907096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mouse models of Huntington's disease and methodological considerations for therapeutic trials.
    Ferrante RJ
    Biochim Biophys Acta; 2009 Jun; 1792(6):506-20. PubMed ID: 19362590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Animal models of Huntington's disease: implications in uncovering pathogenic mechanisms and developing therapies.
    Wang LH; Qin ZH
    Acta Pharmacol Sin; 2006 Oct; 27(10):1287-302. PubMed ID: 17007735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of transgenic and knock-in mice to study Huntington's disease.
    Hickey MA; Chesselet MF
    Cytogenet Genome Res; 2003; 100(1-4):276-86. PubMed ID: 14526189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathogenic mechanisms in Huntington's disease.
    Jones L; Hughes A
    Int Rev Neurobiol; 2011; 98():373-418. PubMed ID: 21907095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Towards a transgenic model of Huntington's disease in a non-human primate.
    Yang SH; Cheng PH; Banta H; Piotrowska-Nitsche K; Yang JJ; Cheng EC; Snyder B; Larkin K; Liu J; Orkin J; Fang ZH; Smith Y; Bachevalier J; Zola SM; Li SH; Li XJ; Chan AW
    Nature; 2008 Jun; 453(7197):921-4. PubMed ID: 18488016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of neuronal cell death in Huntington's disease.
    Sawa A; Tomoda T; Bae BI
    Cytogenet Genome Res; 2003; 100(1-4):287-95. PubMed ID: 14526190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinical and genetic features of Huntington disease.
    Sturrock A; Leavitt BR
    J Geriatr Psychiatry Neurol; 2010 Dec; 23(4):243-59. PubMed ID: 20923757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinico-pathological rescue of a model mouse of Huntington's disease by siRNA.
    Wang YL; Liu W; Wada E; Murata M; Wada K; Kanazawa I
    Neurosci Res; 2005 Nov; 53(3):241-9. PubMed ID: 16095740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mouse models of Huntington's disease.
    Menalled LB; Chesselet MF
    Trends Pharmacol Sci; 2002 Jan; 23(1):32-9. PubMed ID: 11804649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autopsy-proven Huntington's disease with 29 trinucleotide repeats.
    Kenney C; Powell S; Jankovic J
    Mov Disord; 2007 Jan; 22(1):127-30. PubMed ID: 17115386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Huntington's disease: clinical presentation and treatment.
    Novak MJ; Tabrizi SJ
    Int Rev Neurobiol; 2011; 98():297-323. PubMed ID: 21907093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Huntington's disease.
    MacDonald ME; Gines S; Gusella JF; Wheeler VC
    Neuromolecular Med; 2003; 4(1-2):7-20. PubMed ID: 14528049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dysfunctional Dopaminergic Neurones in Mouse Models of Huntington's Disease: A Role for SK3 Channels.
    Dallérac GM; Levasseur G; Vatsavayai SC; Milnerwood AJ; Cummings DM; Kraev I; Huetz C; Evans KA; Walters SW; Rezaie P; Cho Y; Hirst MC; Murphy KP
    Neurodegener Dis; 2015; 15(2):93-108. PubMed ID: 25871323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Huntington disease: pathogenesis and treatment.
    Dayalu P; Albin RL
    Neurol Clin; 2015 Feb; 33(1):101-14. PubMed ID: 25432725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic strategies for Huntington's disease based on a molecular understanding of the disorder.
    Haque NS; Borghesani P; Isacson O
    Mol Med Today; 1997 Apr; 3(4):175-83. PubMed ID: 9134531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Environmental enrichment reduces neuronal intranuclear inclusion load but has no effect on messenger RNA expression in a mouse model of Huntington disease.
    Benn CL; Luthi-Carter R; Kuhn A; Sadri-Vakili G; Blankson KL; Dalai SC; Goldstein DR; Spires TL; Pritchard J; Olson JM; van Dellen A; Hannan AJ; Cha JH
    J Neuropathol Exp Neurol; 2010 Aug; 69(8):817-27. PubMed ID: 20613636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Weight loss in Huntington disease increases with higher CAG repeat number.
    Aziz NA; van der Burg JM; Landwehrmeyer GB; Brundin P; Stijnen T; ; Roos RA
    Neurology; 2008 Nov; 71(19):1506-13. PubMed ID: 18981372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How does the Huntington's disease mutation damage cells?
    Rubinsztein DC
    Sci Aging Knowledge Environ; 2003 Sep; 2003(37):PE26. PubMed ID: 13679594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression, pharmacology and functional activity of adenosine A1 receptors in genetic models of Huntington's disease.
    Ferrante A; Martire A; Pepponi R; Varani K; Vincenzi F; Ferraro L; Beggiato S; Tebano MT; Popoli P
    Neurobiol Dis; 2014 Nov; 71():193-204. PubMed ID: 25132555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.